- ►diabetesjournals.org DG Marrero, J Crean, B Zhang, T Kellmeyer, … - Diabetes care, 2007 - Am Diabetes Assoc RESULTS—Pramlintide-treated patients reported greater treatment satisfaction
in most questionnaire responses. Treatment satisfaction was similar for
pramlintide-treated patients regardless of intensive insulin regimens (MDI ... Cited by 13 - Related articles - BL Direct - All 6 versions
RR Rubin, M Peyrot - Current Medical Research and Opinion®, 2007 - informahealthcare.com Objective: This study was designed to assess treatment satisfaction in patients
using pramlintide who had not previously achieved glycemic targets with insulin
therapy alone. Assessment included the association between treatment ... Cited by 5 - Related articles - BL Direct - All 4 versions
- Free from Publisher S Edelman, S Garg, J Frias, D Maggs, Y Wang, … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—Baseline A1C was 8.1% for both groups and at week 29 had decreased
comparably (pramlintide −0.5% [95% CI −0.61 to −0.33]; placebo −0.5%
[−0.63 to −0.35]). Pramlintide treatment significantly reduced ... Cited by 39 - Related articles - BL Direct - All 10 versions
SA Amiel, SR Heller, IA Macdonald, SL … - Diabetes Obesity and Metabolism, 2005 - interscience.wiley.com Background: Pramlintide, a human amylin analogue, is a potential new adjunctive
therapy to insulin for patients with type 1 diabetes and insulin-using patients
with type 2 diabetes. Early clinical trials have shown a transient ... Cited by 15 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org M Riddle, J Frias, B Zhang, H Maier, C Brown, … - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS— In a 16-week, double-blind, placebo-controlled
study, 212 patients using insulin glargine with or without oral antidiabetes
agents (OAs) were randomized to addition of pramlintide (60 or 120 μg ... Cited by 25 - Related articles - BL Direct - All 5 versions
[CITATION] DIAB. & TE. S Study Group: The DIAB. &TE. S Project: how patients perceive diabetes and …
J Pullman, T Darsow, JP Frias - Vascular Health and Risk Management, 2006 - pubmedcentral.nih.gov In patients with diabetes, dysregulation of multiple glucoregulatory hormones
results in chronic hyperglycemia and an array of associated microvascular and
macrovascular complications. Optimization of glycemic control, both overall ... Cited by 7 - Related articles - BL Direct - All 7 versions
A Young - Amylin: physiology and pharmacology, 2005 - books.google.com Andrew Young Tissue Expression and Secretion of Amylin I. Summary Amylin and
insulin are co-localized within the same secretory granules of
pancreatic/?-cells. Acutely, the secreted ratio of amylinrinsulin is ... Cited by 8 - Related articles - All 3 versions
L Want - The Diabetes Educator, 2006 - tde.sagepub.com Pramlintide, given at mealtimes, is indicated as an adjunct treatment in
patients with type 1 or type 2 diabetes who use mealtime insulin therapy and
have failed to achieve desired glucose control despite optimal insulin ... Cited by 3 - Related articles - BL Direct - All 3 versions
[CITATION] Pramlintide therapy in addition to insulin in type 1 diabetes: effect on metabolic control after …
